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Abstract
Hyperglycemia is the elevation of blood glucose concentrations above the 
normal range. Prolonged uncontrolled hyperglycemia is associated with serious life-
threatening complications. Hyperglycemia arises from an imbalance between glu-
cose production and glucose uptake and utilization by peripheral tissues. Disorders 
that compromise pancreatic function or affect the glucose counter-regulatory 
hormones cause hyperglycemia. Acute or serious illness or injury may also bring 
about hyperglycemia, as can many classes of drugs. Metformin lowers blood glucose 
levels by inhibiting the production of glucose by the liver whilst enhancing uptake 
of circulating glucose and its utilization in peripheral tissues such as muscle and 
adipose tissue. Metformin suppresses hepatic gluconeogenesis by inhibiting mito-
chondrial respiration and causing a reduction of cellular ATP levels. Metformin may 
also modulate the gut-brain-liver axis, resulting in suppression of hepatic glucose 
production. Metformin also opposes the hyperglycemic action of glucagon and may 
ameliorate pancreatic cell dysfunction associated with hyperglycemia. Metformin 
is therefore recommended for use in the prevention of hyperglycemia, including 
drug-induced hyperglycemia, in at risk patients. The benefits of metformin in the 
prevention of hyperglycemia are unmatched despite its contraindications.
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1. Introduction
Chronic hyperglycemia can lead to complications involving damage to the kidneys, 
retina, nervous system and cardiovascular system. In this chapter, we discuss the 
causes of hyperglycemia, including drug-induced hyperglycemia, highlighting the 
importance and approaches to prevention and management of hyperglycemia. We 
focus on the role and rationale for the use of metformin for the prevention of hyper-
glycemia, presenting the evidence that supports its use for this indication.
2. Hyperglycemia
Hyperglycemia, which literally means ‘high blood glucose’ levels, refers to the 
elevation of blood glucose concentrations above the normal range. Specifically, it 
refers to fasting blood glucose levels greater than 7.0 mmol/L (126 mg/dl) or 2-hour 
postprandial blood glucose levels greater than 11.0 mmol/L (200 mg/dl) [1].
2.1 Symptoms and complications
Mild, transient hyperglycemia is largely asymptomatic. However, prolonged 
uncontrolled hyperglycemia is associated with various symptoms including the 
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classic hyperglycemic triad of polyuria, polydipsia, and polyphagia, as well as 
blurred vision, dehydration, weight changes (gain or loss), generalized fatigue, 
abdominal discomfort, nausea, vomiting and muscle cramps [1, 2]. Complications 
arise when the hyperglycemia is severe and/or persists over an extended period. 
Frequent infections, erectile dysfunction and poor wound healing are associated 
with prolonged hyperglycemia. Chronic hyperglycemia can also lead to many seri-
ous life-threatening complications involving damage to the kidneys (nephropathy), 
retina (retinopathy), nervous system (peripheral neuropathy) and cardiovascular 
system (myocardial infarction, stroke) [1–5].
2.2 Causes of hyperglycemia
Blood glucose levels reflect the dynamic balance between, on the one hand, 
dietary glucose absorption and hepatic glucose production and, on the other hand, 
glucose uptake and utilization by peripheral tissues. Except for dietary glucose 
absorption, these complex and interrelated processes are under the control of the 
hormone insulin and, to a lesser extent, other counter-regulatory hormones such 
as glucagon, catecholamines, cortisol and growth hormone [1, 6]. Hyperglycemia 
arises from an imbalance in these processes that determine blood glucose levels.
The greatest quantitative determinant for hyperglycemia is dysfunction in pan-
creatic islet cell activity which affects insulin release from the pancreas in response 
to. The pathophysiology of hyperglycemia also entails a resulting degree of insulin 
resistance and impairment in homeostatic glucose regulation. Insulin resistance 
results in decreased uptake of glucose by insulin-sensitive tissues as well as a conse-
quential increase in endogenous glucose production. This all leads to hyperglycemia 
[7]. The elevation of blood glucose levels during the fasting state is directly propor-
tional to the increase in hepatic glucose production while that of the postprandial 
state is connected to insufficient suppression of glucose output plus a defect in the 
stimulation of insulin hormone on recipient tissues like skeletal muscle [8].
The progression of this imbalance in blood glucose homeostasis over time leads 
to the development of diabetes, a chronic disease affecting glucose metabolism that 
occurs due to either insufficient production of insulin by the pancreas, or inade-
quate response by tissues to insulin [9]. The development of diabetes can be delayed 
or prevented by targeting the early prevention and/or reversal of hyperglycemia, as 
well as by inhibiting the development of hyperin sulinemia-induced insulin resis-
tance [10]. This would also delay progression of predia betic states to diabetes [11].
In addition to diabetes, there are a myriad of other causes of hyperglycemia, 
i.e., non-diabetic hyperglycemia. Disorders that compromise pancreatic func-
tion (pancreatic cancer, cystic fibrosis, chronic pancreatitis, etc.) or affect the 
glucose counter-regulatory hormones (pheochromocytoma, acromegaly, Cushing 
syndrome) cause hyperglycemia. Transient hyperglycemia may arise consequent 
to abnormally high carbohydrates in the diet, dextrose infusion and total parental 
nutrition. Acute or serious illness or injury may also bring about transient hypergly-
cemia referred to as stress hyperglycemia or hospital-related hyperglycemia [1, 12].
Medicines may also induce hyperglycemia [1, 6, 13].
2.3 Drug-induced hyperglycemia
Drug-induced hyperglycemia refers to the clinically relevant elevation of blood 
glucose levels caused by drugs [13]. Whereas drug-induced hyperglycemia is often 
mild and asymptomatic, severe hyperglycemia may occur particularly in predis-
posed patients, such as those with pre-existing pancreatic dysfunction or insulin 




and certain patient factors are known to increase the risk of drug-induced hyper-
glycemia, such as obesity, sedentary lifestyle, stress, illness, history of gestational 
diabetes, or a family history of diabetes [6, 14].
Many classes of drugs have been implicated in causing hyperglycemia via various 
mechanisms. Some drugs cause hyperglycemia by reducing insulin production/
secretion (glucocorticoids, β-receptor antagonists, thiazide diuretics, calcium-
channel blockers, phenytoin, pentamidine, calcineurin inhibitors, protease inhibi-
tors), including by direct damage to pancreatic cells (glucocorticoids, pentamidine, 
statins). Glucocorticoids, β-receptor antagonists and thiazide diuretics also promote 
hepatic glucose production and reduce insulin sensitivity. Other classes of drugs that 
reduce peripheral tissue sensitivity to insulin include atypical antipsychotics, anti-
depressants, oral contraceptives, statins, nucleoside reverse transcriptase inhibitors 
and protease inhibitors [1, 6, 14–16]. Hyperglycemia is one of the common adverse 
effects of the anticancer agent L-asparaginase, which inhibits insulin synthesis by 
depleting available asparagine in pancreatic cells in addition to impairing insu-
lin receptor activity and promoting peripheral tissue resistance to insulin [14]. 
Monoclonal antibodies such as nivolumab and pembrolizumab may cause severe 
hyperglycemia by triggering the autoimmune-mediated destruction of pancreatic 
cells [17, 18]. β2-receptor agonists cause hyperglycemia by promoting hepatic and 
Figure 1. 
Mechanisms of drug-induced hyperglycemia and implicated classes of drugs.
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muscle glucose production [19]. The various mechanisms of drug-induced hypergly-
cemia and the classes of drugs implicated are shown in Figure 1.
The overall occurrence of drug-induced hyperglycemia is not known and would 
obviously vary between individual drugs. There is a lack of data on the burden of 
drug-induced hyperglycemia for specific drugs, and a few studies have attempted 
to address this gap. For example, the incidence of corticosteroid-related hypergly-
cemia in patients treated with high dose corticosteroids has been estimated to be in 
excess 50% [20, 21]. Comparably high prevalence has been reported for clozapine 
[22]. These and other similar findings strongly suggest that the risk of drug-induced 
hyperglycemia (alongside the risk of new-onset diabetes) is real.
The onset of drug-induced hyperglycemia varies on the medication admin-
istered. At the time of or shortly after initiating corticosteroids, blood glucose 
levels may be altered, whereas patients on hydrochlorothiazide may not experi-
ence altered levels for weeks or longer, depending on the dose given. In regard to 
second generation antipsychotics (SGAs), a consensus statement developed by the 
American Diabetes Association (ADA) in conjunction with other medical organiza-
tions recommends monitoring fasting blood glucose for 12 weeks after initiation of 
therapy and annually thereafter in those without diabetes. However, cases involving 
hyperglycemic crises have been reported within weeks of starting SGAs [23].
3. Prevention and management of hyperglycemia
The common medical occurrence of hyperglycemic states has yet to be given 
the due attention it deserves, considering the numerous consequences it bears to 
patients and the healthcare fraternity. The existing reality of numerous patients 
suffering from hyperglycemia of varied cause provides an overwhelming patient 
load, unmatched by the number of specialized providers. However, the manage-
ment of hyperglycemia has continually posed a great challenge mainly from a lack 
of standardized protocols [24]. Currently, lack of knowledge and consensus on 
strategies of management play a significant role in its mismanagement.
Insulin resistance and the resulting compensatory hyperinsulinemia is consid-
ered to preclude the development of type 2 diabetes. Hyperglycemia prophylaxis is 
thus highly attractive based on the numerous socio-economic benefits it confers to 
patients and the healthcare system. Several studies have demonstrated the advan-
tages gained from preventing elevations of blood glucose levels across a divergent 
patient portfolio. Research has broadly focused on management of hyperglycemia 
regardless of the cause, which underlies the common pathways involved in the 
development of hyperglycemia.
3.1 The role of insulin
The primary strategy employed in hyperglycemia management is insulin [25]. 
Consensus arrived at by ADA and European Association for the Study of Diabetes 
(EASD) outline the management of hyperglycemia in type 2 diabetes patients. 
These guidelines have also been adopted in the prevention of hyperglycemia from 
other causes, including drug-induced hyperglycemia. The guidelines recommend 
the use of insulin in all hospitalized patients, with discontinuation of oral hypo-
glycemic medication [26, 27]. Stoppage of the drugs is on the basis that majority of 
hospitalized patients present with concurrent conditions and/or physiological dys-
functions that tend to contraindicate continued use of these medications if already 
prescribed. The pharmacokinetics of oral medication, which tend to have a slow 




Therefore, it is recommended that critically ill patients be treated with a continu-
ous insulin infusion while non-critically ill patients are initiated on subcutaneous 
(SC) insulin. An individualized dose adjustment for insulin is advised across major 
studies [26, 29]. Resumption of oral diabetic agents (ODA) when transitioning from 
inpatient to outpatient setting, with careful consideration given to previous insulin 
dosing, is advised upon successful treatment. A study involving patients without 
diabetes recommended the administration of intravenous (IV) insulin infusion 
in patients with serum blood glucose level values of greater than 10 mmol/L, with 
a target of achieving serum blood glucose levels of 7.8–10 mmol/L in non-critical 
settings and less than 7.8 mmol/L in an outpatient setting [30].
Despite numerous recommendations, challenges faced by providers during 
insulin administration cannot be overlooked. The biggest impediment to insulin 
use in management of drug-induced hyperglycemia in the affected population is 
the unavoidable side effect of hypoglycemia [31]. Unfortunately, insulin treat-
ment is the most common risk factor for inpatient hypoglycemia. The incidence of 
hypoglycemia is approximately 30% in elderly patients, in spite of using low dose 
insulin and oral diabetic agents [28]. This is associated with increased mortality rate 
and prolonged hospital stays. Hence, constant monitoring of blood glucose levels is 
necessary.
Dose adjustments using patients’ weight is perceived to be safe and effective 
as long as close monitoring is done. However, this is not always feasible, let alone 
practical with many patients. So too is the recommendation of individualizing 
glycemic targets for patients based on clinical status, risk of hypoglycemia and 
patient comorbidities, no matter the benefit it confers. This is because the number 
of patients with drug-induced hyperglycemia cannot be matched to the number of 
specialized health care workers required to meet this need.
Herein lies the difficulty as many patients are unable to achieve the close 
monitoring desired, let alone manage the expected side effects in a home-based 
set up. Even in hospitalized patients, lack of protocols for dose adjustment poses 
a hindrance in adequate control of elevated blood glucose levels. Hypoglycemia 
presents a consequential effect that should be carefully considered in hyperglycemia 
management. Any chosen medication, in addition to lifestyle interventions, should 
ideally be one that is safe, effective, economical and with minimal side effects.
3.2 The role of oral antidiabetic medications
Non-insulin medications provide a practical alternative to achieving glycemic 
control. These agents may also confer a non-glycemic benefit whilst regulating the 
fluctuations in blood glucose levels. Alternatives among non-insulin medication 
include metformin, sulphonylureas, glinides, thiazolidinediones, glucagon-like 
peptide-1 (GLP-1) receptor agonists, and sodium–glucose cotransporter2 (SGLT2) 
inhibitors.
However, the side effects of each of these agents must also be considered. For 
example, SGLT2 inhibitors reduce blood glucose levels by preventing proximal 
tubular reabsorption in the kidney. This has been shown to effectively reduce 
glycated hemoglobin A1c (HbA1c) levels by 0.6–1.0%. They are also associated with 
a low risk of hypoglycemia. However, the dehydration side effects make these agents 
contraindicated in renal dysfunction. They also bear an increased risk of urinary 
and genital tract infections and are related with the development of diabetic keto-
acidosis among diabetic patients [32]. Such a profile tends to limit the use of these 
agents. Metformin use is contraindicated in the presence of any possible indication 
for iodinated contrast media and in renal insufficiency while thiazolidinediones 
are associated with fluid retention. On the other hand, sulfonylureas and glinides 
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result in hypoglycemia in most patients while GLP-1 receptor antagonists can cause 
nausea and hence need to be withheld in critical patients. In spite of the many side 
effects of oral diabetic agents and the recommendation of using insulin as first line, 
recent studies have leaned towards the adoption of the oral diabetic agents. The 
drug most endorsed based on clinical evidence has been metformin [33].
4. Metformin for the prevention of hyperglycemia
4.1 Introduction and rationale
The pathophysiology of hyperglycemia entails a degree of insulin resistance 
and results in decreased uptake of glucose by insulin-sensitive tissues as well as a 
consequential increase in endogenous glucose production [7]. Dysfunction in the 
activity of pancreatic islet cells affects insulin release in response to rising blood 
glucose levels. Targeting the prevention and/or reversal of dysglycemia and insulin 
resistance is the principal behind preventing the development of hyperglycemia 
[11]. Any agent used in prevention of hyperglycemia must therefore target these 
pathways, thereby partially or completely eliminating its development.
Metformin can rightfully be considered for hyperglycemia prevention and 
treatment in cases of insulin resistance. Metformin is a first-line agent in treatment 
of type 2 diabetes mellitus. Recent studies have shown it confers a greater benefit to 
patients than the other oral diabetic agents, which has led to its recommendation for 
use in the prevention of hyperglycemia and prediabetes in at risk patients [34–36].
4.2 Mechanisms of action/pharmacodynamics
Metformin prevents hyperglycemia by hastening the clearance of glucose [37, 38]. 
It causes a reduction in hyperglycemia and hyperinsulinemia [39]. This facilitates a 
consequent decline in high insulin and high blood glucose levels, with no effect on 
insulin secretion. The primary mechanism involved in lowering blood glucose levels 
is through improving hepatic and peripheral tissue sensitivity to insulin [40]. It 
inhibits the production of glucose by the liver whilst enhancing uptake of circulating 
glucose and its utilization in peripheral tissues such as muscle and adipose tissue.
Hepatic gluconeogenesis is an energy-demanding process in which synthesis 
of one molecule of glucose from lactate or pyruvate requires four molecules of 
ATP and two molecules of GTP. Metformin suppresses hepatic gluconeogenesis by 
causing a reduction of cellular ATP levels [41]. Molecularly, metformin appears to 
inhibit mitochondrial respiration. The resulting shift in cellular energy balance 
increases the activity of AMP-activated protein kinase (AMPK), which promotes 
the action of insulin and reduces hepatic gluconeogenesis [42]. AMPK acts as a 
cell energy sensor: it plays a role in energy balance at the cellular and body level 
by adapting to changes in the concentration of AMP/ADP relative to ATP [43]. 
Upon activation by a decrease in cellular energy levels, AMPK initiates a change 
from anabolic to catabolic pathways that consume ATP. This stimulates the uptake 
and use of glucose and oxidation of fatty acids, in addition to the suppression of 
hepatic glucose production. Metformin’s’ inhibition of the mitochondrial complex 
is the basis of its effect as observed through the change in the ratios of AMP/ATP 
or ADP/ATP after its administration [44]. Multiple studies have demostrated that 
one of the mechanisms of action of metformin is the disruption of mitochondrial 
complex I [45, 46].
Metformin may also modulate the gut-brain-liver axis through the activation of 




involves activation of protein kinase A (Pka) by GLP-1 in duodenal enterocytes, 
and results in suppression of hepatic glucose production [47]. It has been shown 
that glucocorticoid therapy leads to changes in the activation of AMPK in Cushing’s 
syndrome patients and in vitro in human adipocytes, effects that were reversed with 
metformin in human adipocytes. These indicate the likelihood of converse effects of 
steroids and metformin in the AMPK signaling pathway, as well as the overriding of 
steroid effects by metformin [44, 48]. Supporting studies demonstrate that steroid-
related increase in glucose levels can be prevented with an AMPK activator [49].
Another postulated mechanism of action for metformin is by causing an increase 
in circulating cyclic adenosine monophosphate (cAMP) which in turn opposes the 
hyperglycemic action of glucagon [42, 50]. Metformin has also been postulated to 
increase the concentration of Glucagon-like peptide-1 (GLP-1) by enhancing site 
production as well as subsequently decreasing its degradation in circulation and 
specific tissues via inactivation of the enzyme dipeptide peptidase-4 (DPP-4). 
Additionally, metformin may induce up regulation of GLP-1receptors on beta cell 
surfaces of the pancreas. This can aid in ameliorating the beta cell dysfunction 
associated with hyperglycemia via the enhancement of the role of GLP-1 on glucose 
dependent release of insulin [11].
4.3 Metformin prevents hyperglycemia and hyperinsulinemia
Metformin can rightfully be considered for hyperglycemia prevention and 
treatment in cases of insulin resistance. Metformin has been identified as a first 
line agent in treatment of type 2 diabetes mellitus. Recent studies have shown that 
it confers a greater benefit to patients than the other oral diabetic agents, which 
has led to its recommendation for use in the prevention of prediabetes in at risk 
patients [34, 35, 51]. Presently though, only a few nations have formally adopted 
this proposal such as Poland, Philippines and Turkey but many may adopt it in 
the near future based on the emerging evidence [11]. Metformin overrides most 
of the factors that contribute to poor glycemic management like inaccessibility to 
medicine and fear of developing hypoglycemia. This improves patient perception 
on its use regardless of the minimal side effects. In addition, it has been demon-
strated to confer long term benefit to those who use it prophylactically. A study 
that followed up patients from a diabetes prevention program after 15 years found 
that the metformin treatment arm had a 17% lower incidence for developing type 2 
diabetes than the placebo arm. This was determined using the HbA1c parameter, in 
which 36% of the patients had a risk reduction for diabetes development [34].
In a prospective observational study in persons with normal glucose tolerance 
and hyperinsulinemia, a dose of 2.55 ± 0.2 g/day of metformin restored physiologi-
cal insulin secretion by decreasing fasting and post-glucose load hyperinsulinemia 
in the oral glucose tolerance test (OGTT). Over the observation period, the effect of 
metformin on the reduction of hyperinsulinemia increased over time, peaking after 
1 year of treatment. The ability to lower fasting blood glucose levels also improved 
with time. Fasting blood glucose levels reached normoglycemic range at 3 months 
and remained so until the end of the 1 year observation period, with no develop-
ment of hypoglycemia [39]. A substantial decrease in hyperinsulinemia from high 
blood glucose levels has also been reported in metformin-treated patients based on 
an increase in the uptake of glucose [52]. The enhancement of insulin action reduces 
the load on the beta cells in insulin secretion thus can aid in ameliorating the beta 
cell dysfunction to an extent; this confers an advantage to patients predisposed to 
developing hyperglycemia.
In addition, a randomized controlled study showed that there was no significant 
difference in blood glucose levels between critically ill patients receiving 1000 mg 
Metformin
8
of metformin daily versus a similar spectrum of patients receiving 50 International 
Units (IU) of regular insulin. Furthermore, metformin-treated patients had blood 
glucose levels subside to near-normal range [40]. The targeted desired blood 
glucose levels were achieved with metformin after three days while insulin failed to 
do the same.
4.4 Metformin for drug-induced hyperglycemia
In acute lymphoblastic leukemia patients with drug-induce hyperglycemia, met-
formin monotherapy controlled blood glucose in 12 out of 17 patients, without the 
need for insulin using a median dose of 1000 mg/day for a median of 6 days. Blood 
glucose levels never exceeded 11.1 mmol/L in 8 of the 12 patients. The one patient 
who developed hyperglycemia during relapse re-induction for leukemia treatment 
was effectively controlled using metformin alone [53]. Three of the patients given 
insulin therapy due to high blood glucose levels were eventually weaned off insulin 
to metformin alone. Additionally, in a controlled trial consisting of non-diabetic 
patients on glucocorticoids, metformin prevented an increase of 2-hour glucose 
AUC with, signifying glucose tolerance preservation. No changes in baseline and 
after 4 weeks metformin treatment was seen with the 2-hour glucose AUC whereas 
this parameter increased in the placebo group [54].
Similarly, the effect of metformin on prednisone-induced hyperglycemia (PIH) 
was observed on fasting and 2-hour post prandial glucose levels in hematologi-
cal cancer patients. The fasting blood glucose readings indicated a proportion 
of prednisone-induced hyperglycemia of 72.7% and 14.3% in the control and 
treatment groups respectively. The proportion was slightly lower while using the 
2-hour post prandial glucose, in which 54.5% of participants in the control group 
developed prednisone-induced hyperglycemia while none developed prednisone-
induced hyperglycemia in the treatment group. Patients in the control group had 
16 (95% CI 1.3–194.6) times the odds of developing prednisone-induced hypergly-
cemia compared to patients in the treatment group. Double daily dosing (1700 mg 
twice daily) was more effective in preventing prednisone-induced hyperglycemia 
[21]. This is supported by other studies that show that that a daily dose of metfor-
min 1500 mg contributes to 80–85% glucose lowering effects [55].
4.5 Metformin for hyperglycemia: risks and benefits
The limitations attached to the full exploitation of metformin use include its 
relative contraindications in many hospitalized patients who present with comor-
bidities like renal insufficiency or unstable hemodynamic status. Metformin is 
contraindicated if serum creatinine is ≥133 mmol/L in men or ≥ 124 mmol/L in 
women. Emerging evidence shows that the established cut-off points for renal 
safety may be overly restrictive [56]. It has been argued that there is a need to relax 
these cut-offs and policies to allow use of this drug to patients with stable chronic 
kidney disease characterized by mild–moderate renal insufficiency [57–59].
The associated risk of lactic acidosis tends to deter the use of metformin in 
majority of the comorbid patients on drugs that predispose to the development of 
hyperglycemia. However, the studies that made such recommendations used a small 
percentage of the patient population, thus limiting the extrapolation of these rec-
ommendations to the greater public [60]. Fortunately, the incidence of metformin-
induced lactic acidosis is rare and can be significantly reduced in at-risk patients by 
observing the necessary precautions [27, 56]. Other factors may also play a greater 
role in in being predictors of acidosis, such as dehydration, severe heart and renal 
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Supporting evidence on avoidance of metformin use in certain cases is poor and 
inconsistent such as in patients undergoing radio-contrast imaging which theoreti-
cally predisposes patients to media-induced nephropathy, increasing the risk of 
lactic acidosis [56].
The benefits of metformin in the prevention of hyperglycemia are unmatched 
despite its list of contraindications. This has facilitated its expanded use based on 
its well-founded glycemic effects as well as numerous benefits conferred such as the 
beneficial effect on reduction of development of cardiovascular risk factors [61]. It 
confers good glycemic management that yields a substantial and enduring decrease 
in the onset and progression of micro vascular complications [60].
Moreover, large based clinical trials and systematic reviews have shown its 
beneficial effect of enhancing weight loss, even the weight loss associated with 
medicaments like antipsychotic agents [62, 63].
5. Conclusions
In summary, the suppression of glucose production by metformin’s direct effect 
plus the enhancement of hepatic insulin signaling will curb the development of 
drug-induced hyperglycemia. Metformin has been shown to reduce the incidence of 
hyperglycemia-related complications such as diabetes and risk factors for cardio-
vascular disease in patients with impaired glucose tolerance and fasting blood sugar 
[11, 64, 65]. This has led to its endorsement of use in patients with high risk of 
developing the aforementioned conditions [36].
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